AstraZeneca should stick to its winning formula. It doesn't need a $400bn US mega-merger
News Source
β’Mon, 03 Aug 2026 17:22:28 GMT
π° What Happened
Financial analysts are questioning why AstraZeneca would pursue a $400 billion merger with US drugmaker Bristol Myers Squibb. AstraZeneca has a strong track record under CEO Pascal Soriot, including beating a hostile takeover by Pfizer in 2014. The company successfully bought Alexion in 2021 for $39 billion and expanded into rare disease drugs. Critics say a mega-merger would be risky and goes against Soriot's history of focusing on science, not dealmaking.
π The Backstory
AstraZeneca is the second-biggest company listed in the UK, worth nearly Β£196 billion. Bristol Myers Squibb is a US cancer drug company worth about $133 billion. A merger would create the world's fourth-largest drugmaker. Soriot has been CEO since 2012 and is known for smart licensing deals rather than huge acquisitions. The FT first reported the talks, but neither company has confirmed them officially.
π― Why It Matters
If AstraZeneca does a $400 billion deal, it would reshape the pharmaceutical industry. It could affect drug prices, competition, and the availability of medicines.
Financial analysts are questioning why AstraZeneca would pursue a $400 billion merger with US drugmaker Bristol Myers Squibb. AstraZeneca has a strong track record under CEO Pascal Soriot, including beating a hostile takeover by Pfizer in 2014. The company successfully bought Alexion in 2021 for $39 billion and expanded into rare disease drugs. Critics say a mega-merger would be risky and goes against Soriot's history of focusing on science, not dealmaking.
AstraZeneca is the second-biggest company listed in the UK, worth nearly Β£196 billion. Bristol Myers Squibb is a US cancer drug company worth about $133 billion. A merger would create the world's fourth-largest drugmaker. Soriot has been CEO since 2012 and is known for smart licensing deals rather than huge acquisitions. The FT first reported the talks, but neither company has confirmed them officially.
If AstraZeneca does a $400 billion deal, it would reshape the pharmaceutical industry. It could affect drug prices, competition, and the availability of medicines.